Sector Alpha

Track where the smart money flows in Indian equities

DashboardWeekly UpdateUploadPipelinePE CyclesBrainAbout

Data updated weekly. Not financial advice.

Sector Alpha
  1. Home
  2. /Momentum
  3. /Pharma - Formulators
  4. /Fredun Pharmaceuticals Ltd
MomentumDeep Value

Fredun Pharmaceuticals Ltd: Why Is It Outperforming Nifty 500?

Active
RS +11.0%WeakRe-Entry

In Week of Mar 28, 2026, Fredun Pharmaceuticals Ltd (Pharma - Formulators) is outperforming Nifty 500 with +11.0% relative strength. Fundamentals: Weak.

Avoid

What's Happening

🚫No earnings growth, no valuation discount — limited upside
💰Trading 69% above estimated fair value — significant premium

Earnings Acceleration Triggers

1. High-margin business ramp-up (dermaceutics, pet care, nutritionals)
Next 6-7 quartersMEDIUM
2. Margin expansion from product mix shift
OngoingMEDIUM
3. Revenue visibility from established runway
Next 2-3 yearsMEDIUM

Key Risks

1. Execution risk on high growth trajectory
MEDIUM

Key Numbers

Operating Margin
16.0%
Insufficient Data
PE Ratio
28.4
Current Price
₹1,694
Dividend Yield
0.04%
Fundamental Score
25/100
Weak
Market Cap
927 Cr
Valuation
Significantly Overvalued

12-Week Performance

Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.

12 weeks agoThis week

Why Are Fredun Pharmaceuticals Ltd's Earnings Accelerating?

Based on Q3 FY26 earnings • Updated Mar 14, 2026

High-margin business ramp-up (dermaceutics, pet care, nutritionals)

Expected: Next 6-7 quartersMEDIUM confidence+₹400 Cr revenue

What: Operational efficiencies in specialty segments driving profit jump in next 6-7 quarters

Impact: +₹400 Cr revenue

“Management: 'There will be a sudden growth in the profits even further in the next 2 to 3 years because of the operational efficiencies coming into our high-margin business, especially dermaceutics, especially our pet care, especially our new line of businesses. So you might, in fact, see a further jump in the profits coming in the next 6 to 7 quarters.'”

Margin expansion from product mix shift

Expected: OngoingMEDIUM confidence

What: Strategic shift toward higher-margin specialty products driving EBITDA margin expansion

“Management: 'EBITDA margins improved to 16%, expanded by 384 basis points.'”

Revenue visibility from established runway

Expected: Next 2-3 yearsMEDIUM confidence+₹550 Cr revenue

What: Clear trajectory to reach ₹550-580 cr revenue target within 2-3 years

Impact: +₹550 Cr revenue

“Management: 'That gives us a head -- runway to reach around ₹600 crores and we are comfortable -- and around ₹550 crores, ₹570 crores to ₹580 crores, and we will easily achieve those numbers.'”

What Are the Key Risks for Fredun Pharmaceuticals Ltd?

Earnings deceleration risks from management commentary

Execution risk on high growth trajectory

MEDIUM

Trigger: Operational inefficiencies emerge during rapid scaling

Impact: -200 bps margin impact

Management view: Management expressed confidence but didn't address specific risks in transcript excerpts.

Monitor: Quarterly margin trends vs revenue growth

What Is Fredun Pharmaceuticals Ltd's Management Saying?

Key quotes from recent conference calls

“EBITDA margins improved to 16%, expanded by 384 basis points. — Management”
“That gives us a head -- runway to reach around ₹600 crores and we are comfortable -- and around ₹550 crores, ₹570 crores to ₹580 crores, and we will easily achieve those numbers. — Management”
“There will be a sudden growth in the profits even further in the next 2 to 3 years because of the operational efficiencies coming into our high-margin business, especially dermaceutics, especially our pet care, especially our new line of businesses. So you might, in fact, see a further jump in the profits coming in the next 6 to 7 quarters. — Management”

What Is Fredun Pharmaceuticals Ltd's Management Guidance?

Forward-looking targets from management for Next 6-7 quarters

Implied PAT Growth

100%

Management Tone: BULLISH

Key Milestones

• ₹550-580 cr revenue target

• Profit jump in next 6-7 quarters

How Fast Is Fredun Pharmaceuticals Ltd Growing?

Revenue, profit and margin growth rates

MetricYoY3Y CAGRTrend
OPM16.0%—Insufficient Data

The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Mar 14, 2026.

Other Top Pharma - Formulators Stocks Beating Nifty 500

Sun Pharmaceutical Industries Ltd
Strong • 4w streak
+15.9%
Torrent Pharmaceuticals Ltd
Average • 12w streak
+23.4%
Dr Reddys Laboratories Ltd
Average • 5w streak
+12.6%
Lupin Ltd
Average • 12w streak
+22.1%
Zydus Lifesciences Ltd
Weak
+10.0%
← Back to Pharma - FormulatorsDashboard

Frequently Asked Questions: Fredun Pharmaceuticals Ltd

Based on publicly available financial data. This is educational research, not investment advice.

What were Fredun Pharmaceuticals Ltd's latest quarterly results?

Fredun Pharmaceuticals Ltd's latest quarterly results (Dec 2025) show

  • Operating Margin: 16.0% (insufficient_data)

Is Fredun Pharmaceuticals Ltd's profit growing or declining?

Fredun Pharmaceuticals Ltd's profit is declining with an insufficient_data trend.

  • PAT Growth QoQ: +11.1% (sequential)
  • Trend: Insufficient_data — consistent growth pattern

What is Fredun Pharmaceuticals Ltd's revenue growth trend?

Fredun Pharmaceuticals Ltd's revenue growth trend is insufficient_data.

  • Revenue Growth QoQ: +11.0% (sequential)

How is Fredun Pharmaceuticals Ltd's operating margin trending?

Fredun Pharmaceuticals Ltd's operating margin is insufficient_data.

  • Current OPM: 16.0%
  • OPM Change QoQ: +1.0% basis points

Is Fredun Pharmaceuticals Ltd's growth accelerating or decelerating?

Fredun Pharmaceuticals Ltd's earnings growth is insufficient_data with positive momentum on a sequential basis.

  • Sequential Acceleration: -17.5% bps

Is Fredun Pharmaceuticals Ltd overvalued or undervalued?

Fredun Pharmaceuticals Ltd appears significantly overvalued based on our fair value analysis.

  • Valuation Signal: Significantly Overvalued
  • Current PE: 28.4x
  • Price-to-Book: 5.8x

What is Fredun Pharmaceuticals Ltd's current PE ratio?

Fredun Pharmaceuticals Ltd's current PE ratio is 28.4x.

  • Current PE: 28.4x
  • Market Cap: 927 Cr
  • Dividend Yield: 0.04%

How does Fredun Pharmaceuticals Ltd's valuation compare to its history?

Fredun Pharmaceuticals Ltd's current PE is 28.4x.

  • Current PE: 28.4x
  • Valuation Assessment: Significantly Overvalued

What is Fredun Pharmaceuticals Ltd's price-to-book ratio?

Fredun Pharmaceuticals Ltd's price-to-book ratio is 5.8x.

  • Price-to-Book (P/B): 5.8x
  • Book Value per Share: ₹293
  • Current Price: ₹1694

Is Fredun Pharmaceuticals Ltd a fundamentally strong company?

Fredun Pharmaceuticals Ltd is rated Weak with a fundamental score of 24.69/100. This score is calculated from objective financial metrics

  • PAT Growth QoQ: +11.1% (10% weight)
  • Margins stable (10% weight)

Is Fredun Pharmaceuticals Ltd debt free?

Fredun Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.

  • Total Debt: ₹171 Cr

Is Fredun Pharmaceuticals Ltd's cash flow positive?

Fredun Pharmaceuticals Ltd's operating cash flow is negative (FY2025).

  • Cash from Operations (CFO): ₹-29 Cr
  • Free Cash Flow (FCF): ₹-35 Cr
  • CFO/PAT Ratio: -145% (weak cash conversion)

What is Fredun Pharmaceuticals Ltd's dividend yield?

Fredun Pharmaceuticals Ltd's current dividend yield is 0.04%.

  • Dividend Yield: 0.04%
  • Current Price: ₹1694

Who holds Fredun Pharmaceuticals Ltd shares — promoters, FII, DII?

Fredun Pharmaceuticals Ltd's shareholding pattern (Feb 2026)

  • Promoters: 43.1%
  • FII (Foreign): 1.1%
  • DII (Domestic): 2.9%
  • Public: 53.0%

Is promoter holding increasing or decreasing in Fredun Pharmaceuticals Ltd?

Fredun Pharmaceuticals Ltd's promoter holding has remained stable recently.

  • Current Promoter Holding: 43.1% (Feb 2026)
  • Previous Quarter: 43.1% (Dec 2025)
  • Change: 0.00% (stable)

How long has Fredun Pharmaceuticals Ltd been outperforming Nifty 500?

Fredun Pharmaceuticals Ltd has been outperforming Nifty 500 for 3 consecutive weeks, indicating early-stage outperformance.

Is Fredun Pharmaceuticals Ltd a new momentum entry or an established outperformer?

Fredun Pharmaceuticals Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.

What are the growth catalysts for Fredun Pharmaceuticals Ltd?

Fredun Pharmaceuticals Ltd has 3 key growth catalysts identified from recent earnings analysis

  • High-margin business ramp-up (dermaceutics, pet care, nutritionals)
  • Margin expansion from product mix shift
  • Revenue visibility from established runway

What are the key risks in Fredun Pharmaceuticals Ltd?

Fredun Pharmaceuticals Ltd has 1 key risk worth monitoring

  • Execution risk on high growth trajectory

What did Fredun Pharmaceuticals Ltd's management say in the latest earnings call?

In Q3 FY26, Fredun Pharmaceuticals Ltd's management highlighted

  • "EBITDA margins improved to 16%, expanded by 384 basis points. — Management"
  • "That gives us a head -- runway to reach around ₹600 crores and we are comfortable -- and around ₹550 crores, ₹570 crores to ₹580 crores, and we will e..."
  • "There will be a sudden growth in the profits even further in the next 2 to 3 years because of the operational efficiencies coming into our high-margin..."

What is Fredun Pharmaceuticals Ltd's management guidance for growth?

Fredun Pharmaceuticals Ltd's management has provided the following forward guidance for Next 6-7 quarters

  • Implied PAT growth: 100%
  • Management tone: bullish
  • Milestone: ₹550-580 cr revenue target
  • Milestone: Profit jump in next 6-7 quarters

Is Fredun Pharmaceuticals Ltd worth studying for long term investment?

Based on quantitative research signals, here is why Fredun Pharmaceuticals Ltd may be worth studying

  • Currently showing mixed signals — monitor for clearer trend confirmation

What is the investment thesis for Fredun Pharmaceuticals Ltd?

Fredun Pharmaceuticals Ltd investment thesis summary:

Research Signals (Bull Case)

  • Growth catalyst: High-margin business ramp-up (dermaceutics, pet care, nutritionals)

Risk Factors (Bear Case)

  • Appears significantly overvalued
  • Key risk: Execution risk on high growth trajectory

What is the future outlook for Fredun Pharmaceuticals Ltd?

Fredun Pharmaceuticals Ltd's forward outlook based on current data signals

  • Earnings Trend: insufficient_data
  • Revenue Trend: insufficient_data
  • Margin Trend: insufficient_data
  • Valuation: Significantly Overvalued
  • Key Catalyst: High-margin business ramp-up (dermaceutics, pet care, nutritionals)
  • Key Risk: Execution risk on high growth trajectory

The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.